These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 24266819)

  • 41. Circular RNA Expression Profiling Identifies Prostate Cancer- Specific circRNAs in Prostate Cancer.
    Xia Q; Ding T; Zhang G; Li Z; Zeng L; Zhu Y; Guo J; Hou J; Zhu T; Zheng J; Wang J
    Cell Physiol Biochem; 2018; 50(5):1903-1915. PubMed ID: 30396163
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [PSA and hK2 in the diagnosis of prostate cancer].
    Alapont Alacreu JM; Navarro Rosales S; Budía Alba A; España Furió F; Morera Martínez F; Jiménez Cruz JF
    Actas Urol Esp; 2008 Jun; 32(6):575-88. PubMed ID: 18655340
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The influence of PSA-RNA yield on the analysis of expressed prostatic secretions (EPS) for prostate cancer diagnosis.
    Whelan C; Crocitto L; Kawachi M; Chan K; Smith D; Wilson T; Smith S
    Can J Urol; 2013 Feb; 20(1):6597-602. PubMed ID: 23433128
    [TBL] [Abstract][Full Text] [Related]  

  • 44. PSA and beyond: the past, present, and future of investigative biomarkers for prostate cancer.
    Tosoian J; Loeb S
    ScientificWorldJournal; 2010 Oct; 10():1919-31. PubMed ID: 20890581
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Utilization of screening and treatment of prostate cancer in 2011].
    Tombal B
    Bull Mem Acad R Med Belg; 2011; 166(3-4):170-6; discussion 177. PubMed ID: 22375496
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of increasing the PSA cutoff to perform additional biomarker tests before prostate biopsy.
    Nordström T; Adolfsson J; Grönberg H; Eklund M
    BMC Urol; 2017 Oct; 17(1):92. PubMed ID: 28974201
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Determination of the percentage of free prostate-specific antigen helps to avoid unnecessary biopsies in men with normal rectal examinations and total prostate-specific antigen of 4-10 ng/ml.
    Martínez-Piñeiro L; Tabernero A; Contreras T; Madero R; Lozano D; López-Tello J; Alonso-Dorrego JM; Picazo ML; González Gancedo P; Martínez-Piñeiro JA; de La Peña JJ
    Eur Urol; 2000 Mar; 37(3):289-96. PubMed ID: 10720854
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Serum markers for early detection and staging of prostate cancer. Status report on current and future markers].
    Haese A; Graefen M; Palisaar J; Huland E; Huland H
    Urologe A; 2003 Sep; 42(9):1172-87. PubMed ID: 14504750
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy.
    McKiernan J; Donovan MJ; Margolis E; Partin A; Carter B; Brown G; Torkler P; Noerholm M; Skog J; Shore N; Andriole G; Thompson I; Carroll P
    Eur Urol; 2018 Dec; 74(6):731-738. PubMed ID: 30237023
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Single-molecule catalytic hairpin assembly for rapid and direct quantification of circulating miRNA biomarkers.
    Hu X; Fan J; Duan B; Zhang H; He Y; Duan P; Li X
    Anal Chim Acta; 2018 Dec; 1042():109-115. PubMed ID: 30428976
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [PSA-based parameters].
    Nakashima J
    Nihon Rinsho; 2005 Feb; 63(2):241-6. PubMed ID: 15714973
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Biomarkers for evaluation of prostate cancer prognosis.
    Esfahani M; Ataei N; Panjehpour M
    Asian Pac J Cancer Prev; 2015; 16(7):2601-11. PubMed ID: 25854335
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical utility of emerging biomarkers in prostate cancer liquid biopsies.
    Boerrigter E; Groen LN; Van Erp NP; Verhaegh GW; Schalken JA
    Expert Rev Mol Diagn; 2020 Feb; 20(2):219-230. PubMed ID: 31577907
    [No Abstract]   [Full Text] [Related]  

  • 54. Clinical utility of current biomarkers for prostate cancer detection.
    Kim JH; Hong SK
    Investig Clin Urol; 2021 Jan; 62(1):1-13. PubMed ID: 33381926
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [[-2] proPSA: A Novel Marker of Prostate Cancer].
    Ishikura K
    Rinsho Byori; 2015 Jan; 63(1):84-93. PubMed ID: 26524883
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Associations of circulating 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and vitamin D pathway genes with prostate-specific antigen progression in men with localized prostate cancer undergoing active monitoring.
    Gilbert R; Metcalfe C; Fraser WD; Lewis S; Donovan J; Hamdy F; Neal DE; Lane JA; Martin RM; Tilling K
    Eur J Cancer Prev; 2013 Mar; 22(2):121-5. PubMed ID: 22955340
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multimarker circulating DNA assay for assessing blood of prostate cancer patients.
    Sunami E; Shinozaki M; Higano CS; Wollman R; Dorff TB; Tucker SJ; Martinez SR; Mizuno R; Singer FR; Hoon DS
    Clin Chem; 2009 Mar; 55(3):559-67. PubMed ID: 19131636
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Molecular forms of prostate-specific antigen and human kallikrein 2 as possible indicators in prostatic carcinoma diagnosis].
    Lein M; Stephan C; Jung K; Schnorr D; Loening SA
    Urologe A; 2000 Jul; 39(4):313-23. PubMed ID: 10957772
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Circulating nucleic acids in plasma or serum (CNAPS) as prognostic and predictive markers in patients with solid neoplasias.
    Goebel G; Zitt M; Zitt M; Müller HM
    Dis Markers; 2005; 21(3):105-20. PubMed ID: 16276004
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical Utility of Biomarkers in Localized Prostate Cancer.
    Leapman MS; Nguyen HG; Cooperberg MR
    Curr Oncol Rep; 2016 May; 18(5):30. PubMed ID: 27023445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.